Biomarker Technologies Market by Test Type, Technology, Product, Research, Application, Region – Global Market Size Estimation, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2034
Overview
Global Biomarker Technologies Market was valued at US$ 97.64 Bn. in 2025 and is expected to reach US$ 220.98 Bn. by 2034, at a CAGR of 9.5% during the forecast period.
The biomarker is used as a measurable indicator of the severity or presence of some disease state. More generally a biomarker is anything such as gene, biological molecule, or characteristic that can be used as an indicator of a particular disease state or some other physiological state of a living organism. Biomarker technologies are used in Diagnosis, drug development, and formulation for a contact of definite unsafe chemical and prognostic treatments. The capability of biomarkers to diagnose at an early phase is widely used in cancer analysis and treatment. Biomarkers are using as indicators to estimate and compute pathogenic processes, pharmacological reactions, and biological processes.
Global Biomarker Technologies Market Growth and Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Biomarker Technologies Market Dynamics
The biomarker technologies market is expanding globally under the influence of factors such as increasing incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders. National Cancer Institute (NCI) revealed that approximately 13,397,159 people were affected by various cancer types in the United States in 2011. According to the International Diabetes Federation (IDF), nearly 382 million people were living with diabetes from all over the world in 2013 and this number is expected to reach nearly 592 million by the end of 2034. China and India represent the first and second positions with a high prevalence of diabetes, 98.4 million and 65.1 million respectively.
The growth of the biomarkers market is highly driven by, increasing cases of diseases especially oncology-based disease, increasing demand for disease-specific biomarkers, growing adoption of personalized medicine. Moreover, an increasing utility of biomarkers for diagnostic purposes because of its accuracy, increasing healthcare expenditure, FDA support for biomarkers development, the government taking initiative in more biomarker research, increasing R&D funding by biotechnology companies and research institute, these factors will help to drive the market of biomarkers at xx% CAGR during the forecast period.
On the other hand, a huge amount of capital investment required for the discovery of biomarkers and their development and high cost of biomarkers, this factor may hamper the growth of the biomarkers market during the forecast period.
Biomarker Technologies Market Segment Analysis:
Based on Product Type, the consumables segment accounted for the largest market share of biomarkers in 2025 and is expected to dominate over the others during the forecast period owing to the consumables play a key role in biomarker testing. The consumables market is further segmented into reagents & kits and chromatography columns. In 2025, the reagents & kits segment accounted for the largest share of the consumables market.
By Profiling Technology, the immunoassay segment accounted for the largest share in 2025 and is expected to drive the market of biomarkers in near future. This segment is further divided into ELISA, protein microarray, and western blot. In 2025, the ELISA segment accounted for the largest share of the immunoassay market. ELISA can quantify levels of multiple proteins and have the potential to accelerate the validation of protein biomarkers simultaneously for clinical use, these factors are helpful for the increasing use of ELISA in conformational studies in biomarker discovery.
The omics technology further divided into proteomics, genetics, and transcriptomics. Omics technology is used in the biomarker discovery technologies market. Biomarkers are used in risk assessment, molecular diagnostic, disease diagnosis, DNA fingerprinting, and other molecular applications. The research area is vaster in omics technology
Biomarker Technologies Market Regional Insights:
North America held the largest share of the biomarker technologies in 2025 attributed to the increasing prevalence of diseases such as cancer, autoimmune diseases, cardiovascular diseases & neurological diseases, increasing expenditure on health, and rising geriatric population, these are the factors responsible for the growth of the biomarker technologies market.
Europe had the second-largest market in 2025 and holds a healthy share in the global biomarker technologies market owing to the availability of advanced treatment facilities and established good healthcare infrastructure along with the growing need for efficient and accurate diagnosis and an increasing health expenditure the Asia Pacific is expected to register the highest growth rate from 2020 to 2025 for the biomarker technologies market. The rising incidence of cancer, growing geriatric population, and increasing funds in R&D from private and public organizations for biomarker research, are the factors that will drive the growth of the biomarker technologies market in the Asia Pacific region during the forecast period.
Recent Highlights in Global Biomarker Technologies Market
A group of chemists from UNSW Sydney’s Australian Centre for NanoMedicine (ACN) and biologists from UNSW's Lowy Cancer Research Centre have created a new sensor named “Nanopore blockade sensor” that can detect disease biomarkers in very low concentration in a short time.
The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Biomarker Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence.
Biomarker Technologies Market, Key Highlights:
Global Biomarker Technologies Market analysis and forecast, in terms of value.
Comprehensive study and analysis of market drivers, restraints and opportunities influencing the growth of the Global Biomarker Technologies Market
Global Biomarker Technologies Market segmentation on the basis of type, source, end-user, and region (country-wise) has been provided.
Biomarker Technologies Market strategic analysis with respect to individual growth trends, future prospects along with the contribution of various sub-market stakeholders have been considered under the scope of study.
Global Biomarker Technologies Market analysis and forecast for five major regions namely North America, Europe, Asia Pacific, the Middle East & Africa (MEA) and Latin America along with country-wise segmentation.
Profiles of key industry players, their strategic perspective, market positioning and analysis of core competencies are further profiled.
Competitive developments, investments, strategic expansion and competitive landscape of the key players operating in the Global Biomarker Technologies Market are also profiled.
Biomarker Technologies Market Recent Industry Developments
| Date | Company | Development | Impact |
|---|---|---|---|
| 15 January 2025 | Thermo Fisher Scientific Inc. | Thermo Fisher Scientific launched the Oncomine Precision Assay v2, an advanced next-generation sequencing biomarker panel designed for rapid multi-gene profiling in precision oncology. | The release enhances diagnostic accuracy and streamlines workflow timelines for clinical researchers identifying actionable genomic biomarkers. |
| 22 April 2025 | F. Hoffmann-La Roche Ltd | Roche received FDA clearance for its novel digital immunoassay biomarker test, the Elecsys Amyloid Plasma Panel, aimed at early Alzheimer's disease evaluation. | This milestone accelerates access to non-invasive blood-based biomarker diagnostics, significantly reducing reliance on expensive PET imaging. |
| 18 September 2025 | Quanterix Corporation | Quanterix entered into a strategic collaboration with Eli Lilly and Company to co-develop ultra-sensitive blood-based tau biomarker assays for neurodegenerative clinical trials. | The partnership expands the commercial scaling of Simoa detection technology across large-scale drug development pipelines. |
| 12 November 2025 | Agilent Technologies, Inc. | Agilent completed the acquisition of a specialized spatial biology firm to integrate high-multiplex biomarker imaging capabilities into its companion diagnostics portfolio. | The acquisition broadens Agilent's footprint in tissue-based biomarker profiling and strengthens its position in target validation for pharmaceutical clients. |
| 10 February 2026 | Illumina, Inc. | Illumina announced a commercial partnership with BMS to codevelop liquid biopsy biomarker panels for monitoring minimal residual disease in solid tumors. | This alliance standardizes ctDNA biomarker profiling to drive real-time therapeutic monitoring in clinical oncology workflows. |
Biomarker Technologies Market Scope: Inquire before buying
| Biomarker Technologies Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $97.64 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 9.5% | Market Size in 2034: | US $ 220.98 Bn. |
| Segments Covered: | by Test Type | Solid Biopsy Liquid Biopsy |
|
| by Technology | ddPCR NGS Immunoassay Mass Spectrometry DHPLC Other Technologies |
||
| by Product | Consumables Instruments Services Software/Informatics |
||
| by Research | Genomics Proteomics Metabolomics Metabolic Flux Lipidomics Others Other Research Areas |
||
| by Application | Drug Discovery Diagnostics Personalized Medicine |
||
Biomarker Technologies Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest)
South America (Brazil, Argetina and Rest of South America)
Biomarker Technologies Market Key Players:
1. Thermo Fisher Scientific
2. Bio-Rad Laboratories
3. Danaher Corporation
4. Agilent Technologies
5. Roche
6. Waters Corporation
7. Shimadzu Corporation
8. Illumina, Inc.
9. F. Hoffmann-La Roche AG
10. Merck KGAA
11. PerkinElmer Inc.
12. Siemens Healthcare
13. Abbott Laboratories
14. Qiagen N.V.
15. Biomérieux SA,
16. Becton,
17. Myriad Genetics,
18. Sysmex Corporation,
19. Quest Diagnostics
20. Aushon BioSystem Inc.,
21. Epistem Ltd.
22. Hologic
Frequently Asked Questions:
1. Which region has the largest share in Global Biomarker Technologies Market?
Ans: North America region held the highest share in 2025.
2. What is the growth rate of Global Biomarker Technologies Market?
Ans: The Global Biomarker Technologies Market is growing at a CAGR of 9.5% during forecasting period 2026-2034.
3. What is scope of the Global Biomarker Technologies market report?
Ans: Global Biomarker Technologies Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Biomarker Technologies market?
Ans: The important key players in the Global Biomarker Technologies Market are – Thermo Fisher Scientific, Bio-Rad Laboratories, Danaher Corporation, Agilent Technologies, Roche, Waters Corporation, Shimadzu Corporation, Illumina, Inc., F. Hoffmann-La Roche AG, Merck KGAA, PerkinElmer Inc., Siemens Healthcare, Abbott Laboratories, Qiagen N.V., Biomérieux SA,, Becton,, Myriad Genetics,, Sysmex Corporation,, Quest Diagnostics, Aushon BioSystem Inc.,, Epistem Ltd., and Hologic
5. What is the study period of this market?
Ans: The Global Biomarker Technologies Market is studied from 2020 to 2034.